USA – Adare Pharmaceuticals, a Lawrenceville, NJ-based clinical-stage pharmaceutical company and global provider of advanced pharmaceutical technologies, development and manufacturing, acquired Orbis Biosciences, a Lenexa, KS-based pharmaceutical technology company.
The amount of the deal was not disclosed. The acquisition will enhance Adare’s Pharmaceutical Technologies business, which develops and manufactures products for global pharmaceutical, animal health and over-the-counter (OTC) markets. Orbis Biosciences will maintain its operations in Lenexa and integration of the companies will commence immediately. Led by Maria Flynn, president and CEO, Orbis Biosciences provides enhanced technologies in a scaled, single-step manufacturing process. Its Precision Particle Fabrication® technology can produce uniform particles in size ranges suitable for use in injectable, otic and oral dosage forms. The platform technology accommodates a broad range of active ingredients, including small molecules, peptides, and proteins. Orbis’s proprietary technology includes three platforms: Optimμm® for oral delivery; StratμmTM for injectable delivery; and Unisun® for otic delivery. Led by John Fraher, CEO, Adare Pharmaceuticals utilizes pharmaceutical technology and microbiome scientific platforms to develop novel, improved medicines and therapies for the global market. Technologies include: Microcaps® for taste-masking via a solvent or aqueous based coacervation process; Diffucaps® that incorporates release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals; and the MMTS TM Multi Mini Tablet System in which functional membranes are applied to 1.0-2.0 mm cylindrical tablets to control release rates. The company has developed and manufactured more than 40 products sold by partners in more than 100 countries globally including Lacteol™, Zoolac™, Viactiv™, and a number of branded and complex generic products. Its own product pipeline currently has a number of investigational products in various stages of development, including the lead program, APT-1011 a novel treatment in Phase 3 development for the orphan disease eosinophilic esophagitis (often referred to as EoE). 04/05/2020
